Antigen Delivery to Macrophages Using Liposomal Nanoparticles Targeting Sialoadhesin/CD169

Sialoadhesin (Sn, Siglec-1, CD169) is a member of the sialic acid binding Ig-like lectin (siglec) family expressed on macrophages. Its macrophage specific expression makes it an attractive target for delivering antigens to tissue macrophages via Sn-mediated endocytosis. Here we describe a novel approach for delivering antigens to macrophages using liposomal nanoparticles displaying high affinity glycan ligands of Sn. The Sn-targeted liposomes selectively bind to and are internalized by Sn-expressing cells, and accumulate intracellularly over time. Our results show that ligand decorated liposomes are specific for Sn, since they are taken up by bone marrow derived macrophages that are derived from wild type but not Sn−/− mice. Importantly, the Sn-targeted liposomes dramatically enhance the delivery of antigens to macrophages for presentation to and proliferation of antigen-specific T cells. Together, these data provide insights into the potential of cell-specific targeting and delivery of antigens to intracellular organelles of macrophages using Sn-ligand decorated liposomal nanoparticles.

[1]  K. Marr,et al.  Methods of in vitro macrophage maturation confer variable inflammatory responses in association with altered expression of cell surface dectin-1. , 2008, Journal of immunological methods.

[2]  E. Jones,et al.  Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin. , 2003, Structure.

[3]  F. Batista,et al.  B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. , 2007, Immunity.

[4]  G. Besra,et al.  CD169+ MACROPHAGES PRESENT LIPID ANTIGENS TO MEDIATE EARLY ACTIVATION OF INVARIANT NKT CELLS IN LYMPH NODES , 2010, Nature Immunology.

[5]  J. Irache,et al.  Mannose-targeted systems for the delivery of therapeutics. , 2008, Expert opinion on drug delivery.

[6]  Maureen E. Taylor,et al.  Structural insights into what glycan arrays tell us about how glycan-binding proteins interact with their ligands , 2009, Glycobiology.

[7]  Hiroaki Tateno,et al.  Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. , 2005, Glycobiology.

[8]  T. Sparwasser,et al.  Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. , 2009, Molecular immunology.

[9]  CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells , 2011, The Journal of Immunology.

[10]  J. Garcia-Vallejo,et al.  Glycan modification of the tumor antigen gp100 targets DC‐SIGN to enhance dendritic cell induced antigen presentation to T cells , 2008, International journal of cancer.

[11]  Nan Li,et al.  Cloning and Characterization of Siglec-10, a Novel Sialic Acid Binding Member of the Ig Superfamily, from Human Dendritic Cells* , 2001, The Journal of Biological Chemistry.

[12]  Chuan Wu,et al.  Sialoadhesin-Positive Macrophages Bind Regulatory T Cells, Negatively Controlling Their Expansion and Autoimmune Disease Progression1 , 2009, The Journal of Immunology.

[13]  T. Winkler,et al.  Siglec-G is a B1 cell–inhibitory receptor that controls expansion and calcium signaling of the B1 cell population , 2007, Nature Immunology.

[14]  W. Hubbard,et al.  Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. , 2008, The Journal of allergy and clinical immunology.

[15]  M. Litjens,et al.  Design of neo‐glycoconjugates that target the mannose receptor and enhance TLR‐independent cross‐presentation and Th1 polarization , 2011, European journal of immunology.

[16]  James C Paulson,et al.  In vivo targeting of B-cell lymphoma with glycan ligands of CD22. , 2010, Blood.

[17]  N. Damle,et al.  Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia , 2007, Leukemia.

[18]  J. Domínguez,et al.  Delivery of antigen to sialoadhesin or CD163 improves the specific immune response in pigs. , 2011, Vaccine.

[19]  Y. Liu,et al.  Siglecg Limits the Size of B1a B Cell Lineage by Down-Regulating NFκB Activation , 2007, PloS one.

[20]  G. V. van Dooren,et al.  Dynamics of T cell, antigen-presenting cell, and pathogen interactions during recall responses in the lymph node. , 2009, Immunity.

[21]  Jian Ni,et al.  Siglec-8 , 2000, The Journal of Biological Chemistry.

[22]  Kenneth G. C. Smith,et al.  CD22: an inhibitory enigma , 2008, Immunology.

[23]  H. Nauwynck,et al.  Porcine Arterivirus Attachment to the Macrophage-Specific Receptor Sialoadhesin Is Dependent on the Sialic Acid-Binding Activity of the N-Terminal Immunoglobulin Domain of Sialoadhesin , 2007, Journal of Virology.

[24]  P. Crocker,et al.  Siglecs as positive and negative regulators of the immune system. , 2008, Biochemical Society transactions.

[25]  H. Nauwynck,et al.  IFN-alpha treatment enhances porcine Arterivirus infection of monocytes via upregulation of the porcine Arterivirus receptor sialoadhesin. , 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[26]  J. Paulson,et al.  Sialoside analogue arrays for rapid identification of high affinity siglec ligands. , 2008, Journal of the American Chemical Society.

[27]  Jay K. Nathan,et al.  High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells1 , 2006, The Journal of Immunology.

[28]  H. Nauwynck,et al.  Sialoadhesin and CD163 join forces during entry of the porcine reproductive and respiratory syndrome virus. , 2008, The Journal of general virology.

[29]  James C Paulson,et al.  Siglecs as targets for therapy in immune-cell-mediated disease. , 2009, Trends in pharmacological sciences.

[30]  P. Crocker,et al.  Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake , 2003, Molecular Microbiology.

[31]  Y. Ikehara,et al.  Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[32]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[33]  Jacob P. Brady,et al.  Prolectin, a Glycan-binding Receptor on Dividing B Cells in Germinal Centers , 2009, The Journal of Biological Chemistry.

[34]  H. Favoreel,et al.  Porcine Sialoadhesin (CD169/Siglec-1) Is an Endocytic Receptor that Allows Targeted Delivery of Toxins and Antigens to Macrophages , 2011, PloS one.

[35]  A. Suzuki,et al.  Lymph node macrophages, but not spleen macrophages, express high levels of unmasked sialoadhesin: implication for the adhesive properties of macrophages in vivo. , 2002, Glycobiology.

[36]  Yang Liu,et al.  CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses , 2009, Science.

[37]  D. Jackson,et al.  Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. , 2001, Blood.

[38]  Yasunobu Miyake,et al.  CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. , 2011, Immunity.

[39]  N. Hacohen,et al.  Carbohydrate‐Mediated Targeting of Antigen to Dendritic Cells Leads to Enhanced Presentation of Antigen to T Cells , 2008, Chembiochem : a European journal of chemical biology.

[40]  H. Nakanishi,et al.  Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. , 2008, Cancer letters.

[41]  N. Kawasaki,et al.  CD22 Regulates Adaptive and Innate Immune Responses of B Cells , 2010, Journal of Innate Immunity.

[42]  L. Pulliam,et al.  Sialoadhesin Expressed on IFN-Induced Monocytes Binds HIV-1 and Enhances Infectivity , 2008, PloS one.

[43]  R. Brossmer,et al.  The Ligand-binding Domain of CD22 Is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor Compound , 2002, The Journal of experimental medicine.

[44]  V. Apostolopoulos,et al.  Mannan‐mediated gene delivery for cancer immunotherapy , 2007, Immunology.

[45]  J. Paulson,et al.  Multivalent ligands for siglecs. , 2010, Methods in enzymology.

[46]  N. Bovin,et al.  Eosinophil-Selective Binding and Proapoptotic Effect in Vitro of a Synthetic Siglec-8 Ligand, Polymeric 6′-Sulfated Sialyl Lewis X , 2009, Journal of Pharmacology and Experimental Therapeutics.

[47]  Ajit Varki,et al.  Siglecs and their roles in the immune system , 2007, Nature Reviews Immunology.